Description

Structure

One chewable tablet contains:

active substances: sodium alginate 250 mg, sodium bicarbonate 133.5 mg, and calcium carbonate 80 mg

and excipients:

mint chewable tablets: mannitol 255 mg, macrogol 30 mg, magnesium stearate 4 mg, aspartame 3.75 mg, copovidone 28 mg, potassium acesulfame 3.75 mg, mint flavor 12 mg.

pharmachologic effect

Pharmacotherapeutic group: reflux esophagitis treatment.

ATX code: A02BX.

Pharmacological properties

Pharmacodynamics

When taken orally, Gaviscon reacts quickly with the acidic contents of the stomach.

This forms an alginate gel with an almost neutral pH.

The gel forms a protective barrier on the surface of the stomach contents, preventing gastroesophageal reflux from occurring.

In the case of regurgitation, the gel enters the esophagus, where it reduces mucosal irritation.

Pharmacokinetics

The mechanism of action of the drug Gaviscon is a physical process and does not depend on absorption into the systemic circulation.

Indications

Symptomatic treatment of dyspepsia associated with increased acidity of gastric juice and gastroesophageal reflux (heartburn, acidic eructation), feeling of heaviness in the stomach after eating, including during pregnancy.

Contraindications

Hypersensitivity to any component of the drug.

Side effects

Allergic reactions are possible (urticaria, bronchospasm, anaphylactic reactions).

Interaction

Since the calcium carbonate that is part of the drug exhibits antacid activity, at least 2 hours should elapse between taking Gaviscon and other drugs (especially when taken simultaneously with H2-histamine receptor blockers, antibiotics from the tetracycline group, digoxin, fluoroquinolone, iron salts, ketoconazole, neuroleptics, thyroxine, penicillamine, beta-blockers, glucocorticosteroids, chloroquine and diphosphates).

How to take, course and dosage

Inside after thorough chewing.

Adults and children over 12 years old: 2 - 4 tablets after meals and at bedtime.

Children under 12 years of age: as directed by a doctor.

Elderly patients: No dose change is required for this age group.

Overdose

Symptoms: Abdominal bloating may occur.

Treatment: symptomatic.

Special instructions

In a dose of four tablets, the sodium content is 246 mg (10.6 mmol).

This should be taken into account when it is necessary to follow a diet with very limited salt content, for example, in some cases of congestive heart failure and with impaired renal function.

Each dose of four tablets contains 320 mg (3.2 mmol) of calcium carbonate.

Caution should be exercised when treating patients with hypercalcemia, nephrocalciposis, and recurrent calcium-containing kidney stones.

Due to its aspartame content, this drug should not be administered to patients with phenylketonuria.

There is a possibility of reducing the effectiveness of the drug in patients with very low levels of gastric acidity.

If symptoms persist within seven days after treatment, the clinical condition must be re-evaluated.

Effect on the ability to drive machinery and a car

The drug does not affect the ability to drive vehicles and mechanisms, as well as to engage in other potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.

Release form

Round, flat with beveled edges, tablets, from almost white to creamy color with small splashes, with a mint odor.

On one side of the tablet: an image of a circle and a sword, on the other side: G 250.

Name ENG

GAVISCON

Clinical and pharmacological group

Antacid drug

ATX code

Other antiulcer drugs

Dosage

80mg + 250mg + 133.5mg

Structure

One chewable tablet contains: active substances: sodium alginate 250 mg, sodium bicarbonate 133.5 mg, and calcium carbonate 80 mg

and excipients: chewable mint tablets: mannitol 255 mg, macrogol 30 mg, magnesium stearate 4 mg, aspartame 3.75 mg, copovidone 28 mg, potassium acesulfame 3.75 mg, mint flavor 12 mg.

Indications

Symptomatic treatment of dyspepsia associated with increased acidity of gastric juice and gastroesophageal reflux (heartburn, acidic eructation), feeling of heaviness in the stomach after eating, including during pregnancy.

Storage conditions and periods

At a temperature not higher than 30 degrees.

Expiration date: 2 years

INN / Active ingredient

Sodium alginate, Sodium bicarbonate, Calcium carbonate

Contraindications

Contraindications: hypersensitivity to any component of the drug

phenylketonuria (see the section Special instructions")

children under 12 years of age.,

Carefully:

If you have the following diseases or conditions, you should consult a doctor before using the drug: hypercalcemia, nephrocalcinosis and urolithiasis with the formation of calcium oxalate stones, congestive heart failure, and renal dysfunction.

Specifications